FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038378503> ?p ?o ?g. }

• W2038378503 endingPage "125" @default.
• W2038378503 startingPage "114" @default.
• W2038378503 abstract "Background: Cyclooxygenase-2-specific anti-inflammatory drugs (coxibs) and nonspecific nonsteroidal anti-inflammatory drugs have been shown to inhibit experimental fracture-healing. The present study tested the hypothesis that these effects are reversible after short-term treatment. Methods: With use of a standard model of fracture-healing, identical ED50 dosages of either a nonsteroidal anti-inflammatory drug (ketorolac), a coxib (valdecoxib), or vehicle (control) were orally administered to rats for either seven or twenty-one days and fracture-healing was assessed with biomechanical, histological, and biochemical analyses. Results: When healing was assessed at twenty-one days, the seven-day treatment produced only a trend for a higher rate of nonunion in valdecoxib and ketorolac-treated animals as compared with controls. No differences were observed at thirty-five days. The twenty-one-day treatment produced significantly more nonunions in valdecoxib-treated animals as compared with either ketorolac-treated or control animals (p < 0.05), but these differences disappeared by thirty-five days. The dose-specific inhibition of these drugs on prostaglandin E2 levels and the reversibility of the effects after drug withdrawal were assessed in fracture calluses and showed that ketorolac treatment led to twofold to threefold lower levels of prostaglandin E2 than did valdecoxib. Withdrawal of either drug after six days led to a twofold rebound in these levels by fourteen days. Histological analysis showed delayed remodeling of calcified cartilage and reduced bone formation in association with valdecoxib treatment. Conclusions: Cyclooxygenase-2-specific drugs inhibit fracture-healing more than nonspecific nonsteroidal anti-inflammatory drugs, and the magnitude of the effect is related to the duration of treatment. However, after the discontinuation of treatment, prostaglandin E2 levels are gradually restored and the regain of strength returns to levels similar to control. Clinical Relevance: While animal studies have suggested that both nonsteroidal anti-inflammatory drugs and coxibs inhibit bone repair, there have been no clinical reports with Level-1 evidence to support these findings. Because most patients discontinue these medications when pain has subsided, it is important to determine whether the inhibitory effects are reversible. The present animal study confirms that inhibition of cyclooxygenase 2 impairs fracture-healing and that the effects are dependent on both the dose and duration of treatment. However, the reduced prostaglandin levels in callus rebound with drug withdrawal, and the impairment in the mechanical integrity of the healing fractures is reversed after short-term treatment." @default.
• W2038378503 created "2016-06-24" @default.
• W2038378503 creator A5005029704 @default.
• W2038378503 creator A5006498611 @default.
• W2038378503 creator A5041583266 @default.
• W2038378503 creator A5041819903 @default.
• W2038378503 creator A5044557394 @default.
• W2038378503 creator A5053051638 @default.
• W2038378503 creator A5063351158 @default.
• W2038378503 creator A5079388461 @default.
• W2038378503 creator A5081041296 @default.
• W2038378503 date "2007-01-01" @default.
• W2038378503 modified "2023-10-01" @default.
• W2038378503 title "Selective and Nonselective Cyclooxygenase-2 Inhibitors and Experimental Fracture-Healing" @default.
• W2038378503 cites W1892257529 @default.
• W2038378503 cites W1967495045 @default.
• W2038378503 cites W1974280648 @default.
• W2038378503 cites W1979242330 @default.
• W2038378503 cites W1984588551 @default.
• W2038378503 cites W1984701700 @default.
• W2038378503 cites W1992764172 @default.
• W2038378503 cites W2001162433 @default.
• W2038378503 cites W2012571546 @default.
• W2038378503 cites W2018716226 @default.
• W2038378503 cites W2020563114 @default.
• W2038378503 cites W2025061038 @default.
• W2038378503 cites W2032491472 @default.
• W2038378503 cites W2035047137 @default.
• W2038378503 cites W2052192250 @default.
• W2038378503 cites W2053475304 @default.
• W2038378503 cites W2073184155 @default.
• W2038378503 cites W2080178855 @default.
• W2038378503 cites W2102254877 @default.
• W2038378503 cites W2135231814 @default.
• W2038378503 cites W2140908408 @default.
• W2038378503 cites W2149233326 @default.
• W2038378503 cites W2154879871 @default.
• W2038378503 cites W2176101211 @default.
• W2038378503 cites W2395704271 @default.
• W2038378503 cites W2725056820 @default.
• W2038378503 cites W28782474 @default.
• W2038378503 cites W2988816971 @default.
• W2038378503 cites W4236708194 @default.
• W2038378503 cites W4251038979 @default.
• W2038378503 cites W4255366786 @default.
• W2038378503 doi "https://doi.org/10.2106/jbjs.f.00495" @default.
• W2038378503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17200318" @default.
• W2038378503 hasPublicationYear "2007" @default.
• W2038378503 type Work @default.
• W2038378503 sameAs 2038378503 @default.
• W2038378503 citedByCount "107" @default.
• W2038378503 countsByYear W20383785032012 @default.
• W2038378503 countsByYear W20383785032013 @default.
• W2038378503 countsByYear W20383785032014 @default.
• W2038378503 countsByYear W20383785032015 @default.
• W2038378503 countsByYear W20383785032016 @default.
• W2038378503 countsByYear W20383785032017 @default.
• W2038378503 countsByYear W20383785032018 @default.
• W2038378503 countsByYear W20383785032019 @default.
• W2038378503 countsByYear W20383785032020 @default.
• W2038378503 countsByYear W20383785032021 @default.
• W2038378503 countsByYear W20383785032022 @default.
• W2038378503 countsByYear W20383785032023 @default.
• W2038378503 crossrefType "journal-article" @default.
• W2038378503 hasAuthorship W2038378503A5005029704 @default.
• W2038378503 hasAuthorship W2038378503A5006498611 @default.
• W2038378503 hasAuthorship W2038378503A5041583266 @default.
• W2038378503 hasAuthorship W2038378503A5041819903 @default.
• W2038378503 hasAuthorship W2038378503A5044557394 @default.
• W2038378503 hasAuthorship W2038378503A5053051638 @default.
• W2038378503 hasAuthorship W2038378503A5063351158 @default.
• W2038378503 hasAuthorship W2038378503A5079388461 @default.
• W2038378503 hasAuthorship W2038378503A5081041296 @default.
• W2038378503 hasConcept C126322002 @default.
• W2038378503 hasConcept C141071460 @default.
• W2038378503 hasConcept C181199279 @default.
• W2038378503 hasConcept C185592680 @default.
• W2038378503 hasConcept C2777956040 @default.
• W2038378503 hasConcept C2778446825 @default.
• W2038378503 hasConcept C2778484676 @default.
• W2038378503 hasConcept C2778582115 @default.
• W2038378503 hasConcept C2779528491 @default.
• W2038378503 hasConcept C2779689624 @default.
• W2038378503 hasConcept C2779826273 @default.
• W2038378503 hasConcept C2780820201 @default.
• W2038378503 hasConcept C42219234 @default.
• W2038378503 hasConcept C55493867 @default.
• W2038378503 hasConcept C71924100 @default.
• W2038378503 hasConcept C8337478 @default.
• W2038378503 hasConcept C98274493 @default.
• W2038378503 hasConceptScore W2038378503C126322002 @default.
• W2038378503 hasConceptScore W2038378503C141071460 @default.
• W2038378503 hasConceptScore W2038378503C181199279 @default.
• W2038378503 hasConceptScore W2038378503C185592680 @default.
• W2038378503 hasConceptScore W2038378503C2777956040 @default.
• W2038378503 hasConceptScore W2038378503C2778446825 @default.
• W2038378503 hasConceptScore W2038378503C2778484676 @default.
• W2038378503 hasConceptScore W2038378503C2778582115 @default.

• next